{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T16:01:41Z","timestamp":1765382501745},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2023.100403","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T06:43:50Z","timestamp":1703400230000},"page":"100403","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India"],"prefix":"10.1016","volume":"21","author":[{"given":"Akhilesh","family":"S","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunim","family":"shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Ashish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitish","family":"kumar Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhay","family":"kumar Yadav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Royana","family":"singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2023.100403_bib0001","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","article-title":"Translation of the Philadelphia chromosome into therapy for CML","volume":"112","author":"Druker","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lrr.2023.100403_bib0002","first-page":"513","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lrr.2023.100403_bib0003","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2005.01.020","article-title":"AMN107: tightening the grip of imatinib","volume":"7","author":"O'Hare","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lrr.2023.100403_bib0004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'hare","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lrr.2023.100403_bib0005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","article-title":"Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial)","volume":"24","author":"Fujisawa","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.lrr.2023.100403_bib0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lrr.2023.100403_bib0007","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1073\/pnas.162140299","article-title":"Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop","volume":"99","author":"Roumiantsev","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.lrr.2023.100403_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.lrr.2023.100403_bib0009","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.lrr.2023.100403_bib0010","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1200\/GO.21.00058","article-title":"Spectrum of BCR-ABL mutations and treatment outcomes in ethiopian imatinib-resistant patients with chronic myeloid leukemia","volume":"7","author":"Tadesse","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"10.1016\/j.lrr.2023.100403_bib0011","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4103\/ijmpo.ijmpo_115_17","article-title":"The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: single-institutional experience over 13 years","volume":"38","author":"Chaitanya","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.lrr.2023.100403_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.31557\/apjcb.2021.6.3.225-227","article-title":"A Study on BCR-ABL kinase domain mutations in chronic myeloid leukemia from Western India","volume":"6","author":"Gadhia","year":"2021","journal-title":"Asian Pac. J. Cancer Biol."},{"key":"10.1016\/j.lrr.2023.100403_bib0013","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.4491.4491","article-title":"Imatinib resistance mutation analysis pattern in chronic myeloid leukemia (CML) patients on Imatinib in Indian population","volume":"116","author":"Goyal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2023.100403_bib0014","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:09:59Z","timestamp":1718903399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048923000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":14,"alternative-id":["S2213048923000432"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100403","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100403"}}